Medicinal product name Yaldigo 1600 mg modified-release tablets
Pharmaceutical form Modified release tablet
Strength 1600 mg 
Information from the MAH on shortages No information on expected shortages
Availability of medicinal product
Product No.Package sizeWholesalers' stock state
18-0046-01 KZSLN30 Is available
Legal status Rx Prescription (Pr.)
KZSL Next lowest cost medicine
Package leaflet MS Word document 15-07-2021
Summary of product characteristics MS Word document 15-07-2021
ATC code A07EC02 Antidiarrheals, intestinal antiinflammatory/antiinfective agents

Important notice

Additional information regarding the use for persons aged 75+

If used as "ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS"
SubstanceClassComment
MesalazinumASuitable for older persons. Do not use in severe renal insufficiency.

Medicinal products (3)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Is available (according to the information provided by wholesalers)
(132 containers)
Tamro, Oribalt Rīga, Recipe Plus, Magnum Medical, Euroaptieka N30
(1600 mg)
PVC/Al blister 49.08 
KZSL*
18-0046-01 Labelling text Labelling text Feb 28, 2019
Labelling text Labelling text Feb 28, 2019
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N60
(1600 mg)
PVC/Al blister    18-0046-02 Labelling text Labelling text Feb 28, 2019
Labelling text Labelling text Feb 28, 2019
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N90
(1600 mg)
PVC/Al blister    18-0046-03 Labelling text Labelling text Feb 28, 2019
Labelling text Labelling text Feb 28, 2019
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. 18-0046
Date of authorisation Feb 16, 2018
MA valid until Feb 15, 2023
Marketing authorisation holder, country Tillotts Pharma AB, Sweden